Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in ...

(NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adults and adolescents aged 12 years and older with ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria . Approval based on phase 3 studies demonstrating Dupixent signifi ...

The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.

A clinical trial conducted in a neonatal intensive care unit has identified a new treatment protocol to improve lung growth and function among preterm infants.

Have top stories from The Daily Pennsylvanian delivered to your inbox every day, Monday through Friday, when Penn classes are in session.